Suppression of cesium-induced ventricular tachyarrhythmias by atrial natriuretic peptide in rabbits.
BACKGROUND
Intravenous injection of cesium chloride (Cs) causes ventricular tachyarrhythmias in rabbits. We investigated whether these tachyarrhythmias were caused by increased pressure load and whether they could be suppressed by atrial natriuretic peptide (ANP).


RESULTS
Cs was injected in a bolus dose (1.5 mmol/kg), which was repeated 20 minutes later. Rabbits were then divided into 3 groups: control, ANP-treated, and hydralazine-treated groups. ANP or hydralazine was administered between the first and second Cs injections. The experiments were performed during intrinsic sinus rhythm (protocol A) or during ventricular pacing (protocol B). In protocol A, the second injection of Cs in the control group induced early afterdepolarizations and ventricular tachycardia, which were preceded by a marked increase in left ventricular end-diastolic pressure (LVEDP). Both ANP and hydralazine significantly suppressed Cs-induced increase in LVEDP. The arrhythmia score after the second injection of Cs was significantly lower in the ANP-treated and hydralazine-treated group compared with the control group (P < .005 and P < .05, respectively). In protocol B, the duration of left ventricular monophasic action potential and early afterdepolarization amplitude before and/or after the injections of Cs did not differ significantly between control and ANP-treated groups.


CONCLUSIONS
Our results suggest that increased pressure load may play a role in the arrhythmogenic effect of Cs. The protective effect of ANP against Cs-induced ventricular tachycardia may be explained in part by a reduction in pressure overload. However, this effect might also be explained by the diverse action of ANP on the cardiovascular system.
Ooie
T
T
Department of Internal Medicine I, School of Medicine, Oita Medical University, Hasama, Japan.
Takahashi
N
N
Saikawa
T
T
Iwao
T
T
Hara
M
M
Sakata
T
T
D000200:Action Potentials; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002586:Cesium / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D002712:Chlorides / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D003971:Diastole / Q000187:drug effects; D006830:Hydralazine / Q000494:pharmacology; D008297:Male; D011817:Rabbits; D017180:Tachycardia, Ventricular / Q000139:chemically induced / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology; D016277:Ventricular Function, Left / Q000187:drug effects*
D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002712:Chlorides; D014665:Vasodilator Agents; D002586:Cesium; D006830:Hydralazine; D009320:Atrial Natriuretic Factor; C028019:cesium chloride